← Back to Search

Combination Product

VCTX210A unit for Type 1 Diabetes

Phase 1
Waitlist Available
Research Sponsored by CRISPR Therapeutics AG
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from implantation up to 6 months post implantation
Awards & highlights

Study Summary

This trial is testing a new medication for safety and how well it is tolerated in patients with type 1 diabetes.

Eligible Conditions
  • Type 1 Diabetes
  • Diabetes
  • Endocrine Disorders
  • Autoimmune Diseases
  • Immune System Disorders
  • Metabolic Diseases

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from implantation up to 6 months post implantation
This trial's timeline: 3 weeks for screening, Varies for treatment, and from implantation up to 6 months post implantation for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence of adverse events with causality related to VCTX210A units and/or the surgical procedures required to implant and explant the VCTX210A units.
Secondary outcome measures
Incidence of new alloreactive antibodies found in the blood of patients post implantation.
Incidence of new autoreactive antibodies found in the blood of patients post implantation.
Qualitative evaluation of immune response to VCTX210A units assessed by histological staining for markers of host adaptive immune cells within the graft.
+3 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: VCTX210A combination productExperimental Treatment1 Intervention
Up to seven (7) units will be implanted
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
VCTX210A unit
2022
Completed Phase 1
~10

Find a Location

Who is running the clinical trial?

ViaCyteIndustry Sponsor
6 Previous Clinical Trials
193 Total Patients Enrolled
CRISPR Therapeutics AGLead Sponsor
8 Previous Clinical Trials
885 Total Patients Enrolled
Manasi Jaiman, MD, MPHStudy DirectorViaCyte
2 Previous Clinical Trials
89 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
An Open-Label, FIH Study Evaluating the Safety and Tolerability of VCTX210A Combination Product in Subjects With T1D
2022. "An Open-Label, FIH Study Evaluating the Safety and Tolerability of VCTX210A Combination Product in Subjects With T1D". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05210530.
~2 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top